Viewing Study NCT06206382



Ignite Creation Date: 2024-05-06 @ 7:58 PM
Last Modification Date: 2024-10-26 @ 3:18 PM
Study NCT ID: NCT06206382
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-01-16
First Post: 2024-01-02

Brief Title: Surgical Results of Resection of Locally Advanced Pancreatic Cancer
Sponsor: Assiut University
Organization: Assiut University

Study Overview

Official Title: Surgical Outcome of Borderline Resectable Pancreatic Cancer Upfront Surgery Versus Neoadjuvant Chemotherapy Single Center Experience
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim is to compare the surgical outcomes between upfront surgery and surgery after neoadjuvant chemotherapy in terms of morbidity and mortality
Detailed Description: Pancreatic cancer is the fourth leading cause of cancer death in the United States While surgical resection remains the only curative option more than 80 of patients present with unresectable disease Unfortunately even among those who undergo resection the reported median survival is 15-23 mo with a 5-year survival of approximately 20 Disappointingly over the past several decades despite improvements in diagnostic imaging surgical technique and chemotherapeutic options only modest improvements in survival have been realized Nevertheless it remains clear that surgical resection is a prerequisite for achieving long-term survival and cure The concept of borderline resectable pancreatic cancer has evolved from several clinical observations made over decades It has been recognized for some time that the prognosis for patients undergoing surgical resection for pancreatic ductal adenocarcinoma PDAC is highly dependent on margin status with total gross excision and histologically negative margins R0 resection being associated with the best outcomes Survival for patients who undergo total gross excision but have histologically positive margins R1 resection have a reduced survival in most series

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None